Stocktoria
Novartis AG NOVN.SW
CH · SIX Swiss Exchange · XSWX · stock · Healthcare · website
Novartis AG financials (annual, from 10-K)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $56.7B | $51.7B | $46.7B | $43.5B |
| Gross profit | $43.0B | $38.9B | $34.2B | $31.9B |
| R&D expense | $11.2B | $10.0B | $11.4B | $9.2B |
| SG&A expense | $13.2B | $12.6B | $12.5B | $12.2B |
| Operating income | $17.6B | $14.5B | $9.8B | $7.9B |
| Interest expense | $1.1B | $1.0B | $855.0M | $800.0M |
| Income tax | $2.4B | $1.7B | $551.0M | $1.1B |
| Net income | $14.0B | $11.9B | $14.8B | $7.0B |
| EPS (diluted) | $7.15 | $5.87 | $7.10 | $3.17 |
| Operating cash flow | $19.1B | $17.6B | $14.5B | $14.2B |
| Free cash flow | $15.2B | $13.8B | $11.7B | $12.0B |
| Cash & equivalents | $11.4B | $11.5B | $13.4B | $7.5B |
| Inventory | $6.3B | $5.7B | $5.9B | $7.2B |
| Total assets | $110.9B | $102.2B | $99.9B | $117.5B |
| Total liabilities | $64.4B | $58.1B | $53.2B | $58.0B |
| Shareholders' equity | $46.1B | $44.0B | $46.7B | $59.3B |
Growth · year-over-year · Revenue CAGR 9.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +9.6% | +10.8% | +7.4% | — |
| Net income growth | +17.1% | -19.6% | +113.5% | — |
| EPS growth | +21.8% | -17.3% | +124.0% | — |
| Free cash flow growth | +10.4% | +17.9% | -2.4% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: company filings via Yahoo Finance · CH · as of 2025-12-31. Figures in CHF; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.